Three Pre-Rule Studies of Chlorpyrifos: Nolan et al.
Three Pre-Rule Studies of Chlorpyrifos: Nolan et al. (1982) Honeycutt & DeGeare (1993) Kisicki et al. (1999) Human Studies Review Board June 24, 2009 1 Sequence of Presentations Introduction and Context Anna Lowit, Ph.D. Science Assessments Nolan and Kisicki Studies John Doherty, Ph.D., DABT Honeycutt & Degeare Study
Wade Britton, MPH Ethics Assessments John Carley 2 Chlorpyrifos Introduction and Context Anna Lowit, Ph.D. Senior Scientist Health Effects Division Office of Pesticide Programs 3 Introduction Chlorpyrifos:
Organophosphate pesticide which was first registered in 1965 In June 2000: The technical registrants entered into an agreement with the Agency to eliminate and phase out nearly all uses that result in residential exposures. Human health risk assessment developed for the Interim Registration Eligibility Decision (IRED) relied on adult ChE data from rodents & dogs Human studies were not used to inform point of departure or uncertainty factors Honeycutt study used in the worker exposure assessment 4 Introduction Current regulatory activities leading to
new risk assessment: Registration review: 15-year review cycle under FIFRA for registered pesticides Update human health & ecological risk assessments Petition by Natural Resources Defense Council (NRDC) and Pesticide Action Network, North America (PANNA) to revoke all tolerances and cancel all registered uses 5 Introduction Draft Science Issue Paper reviewed by the FIFRA SAP in 2008 Review the new science from animal & humans
under the context of human health risk assessment Focus on effects in pregnant women, fetuses, and juveniles as these groups are thought to be more susceptible to chlorpyrifos Age-dependant metabolism Epidemiology studies in mothers & children Rodent studies evaluating non-cholinergic toxicities (i.e., behavior, learning, biochemical responses) AChE studies in pregnant rats, fetuses, post-natal pups 6 Human Experimental Studies Nolan Honeycutt Kisicki Purpose Absorption, distribution,
excretion Agricultural re-entry worker exposure NOEL for RBC AChEI Date 1981-82 1991-92 1998 Location Dow Chemical Midland MI Citrus Groves in Kern & Tulare Counties, CA MDS-Harris Labs
Lincon NE Subjects 6M 15 M 30 M 30 F Exposure Single oral dose Single dermal dose Uncontrolled occupational exposure Single oral dose Endpoints of primary concern
RBC ChEI Plasma ChEI Blood TCP Urine TCP RBC ChEI Plasma ChEI Urine TCP RBC ChEI Blood TCP Urine TCP 7 Proposed Uses of the Human For Bounding Analyses Studies Comparing blood & urine data from the human experimental studies with data from animal studies & human epidemiology studies Comparing levels of AChE/ChE inhibition in humans and animals
To Develop & Refine PBPK models Physiologically-based pharmacokinetic models Current models include Nolan et al data Kisicki et al or Honeycutt & DeGeare not used in current model parameterization 8 EPA does NOT propose to use data from the human experimental studies for a point of departure (PoD) or to directly inform the inter-species uncertainty factor Animal studies provide high-quality dose-response data for ChEI across many doses & multiple life stages Human studies lack dose-response information Nolan et al used only one dose level for each route of administration Kisicki et al showed ChEI in only one subject Honeycutt & DeGeare was not designed for dose response Human studies do not address non-cholinergic toxicities Animal data indicate susceptibility of the developing nervous system to chlorpyrifos
Epidemiology studies in children generally support the animal studies 9 Using Human Biomarker Data: Bounding Estimates Rodent Administered Dose, Known & Controlled Blood &/or Urine Measures Human Deliberate Dosing Administered Dose, Known & Controlled Blood &/or Urine Measures Human Epidemiology Exposure, Limited & Uncertain
Blood &/or Urine Measures 10 Physiologically-Based Pharmacokinetic (PBPK) Models Represent the anatomy & physiology of the rodent/human Provide simulations of biological processes such as absorption, distribution, metabolism & elimination Widely recognized as the gold standard in human health risk assessment
Particularly helpful in extrapolations: Route to route Inter-species Across dose range 11 SAP Response SAP was generally supportive of EPAs preliminary conclusions, and identified areas for revision & additional analysis Overall, the Panel agreed that the human deliberate dosing studies contain scientifically useful information for risk assessment, but not for directly establishing PoD or uncertainty factors. The Panel appreciated the Agencys scientific analysis to compare the blood levels in the deliberate dosing and
epidemiological studies, and considered it critically important to maximally use the information from these studies . . . as a basis to bound the reference doses/concentrations . . . The Panel encouraged the Agency to consider the use of a PBPK model to widen the application of these bounding data for current or potential human exposures and for the final reference dose or reference concentrations. 12 Human Experimental Studies Nolan et al (1984) Historically used to interpret biomonitoring studies (e.g., NHANES & worker) Provides estimate of dermal absorption Used in current PBPK models for interspecies scaling
13 Human Experimental Studies Kisicki et al (1999) Lack of plasma ChE is a critical omission from study design decreases its utility Possible reduced absorption of chlorpyrifos from capsule Used in 2002 Timchalk et al PBPK paper For purposes of model evaluation Not used in current parameterization 14 Human Experimental Studies Honeycutt & DeGeare Will be used in combination with other
available worker biomonitoring studies to evaluate range of urinary TCP concentrations for workers 15 Human Experimental Studies Nolan Honeycutt Kisicki Purpose Absorption, distribution, excretion Agricultural re-entry worker exposure NOEL for RBC AChEI Date
1981-82 1991-92 1998 Location Dow Chemical Midland MI Citrus Groves in Kern & Tulare Counties, CA MDS-Harris Labs Lincon NE Subjects 6M 15 M
30 M 30 F Exposure Single oral dose Single dermal dose Uncontrolled occupational exposure Single oral dose Endpoints of primary concern RBC ChEI Plasma ChEI Blood TCP Urine TCP RBC ChEI Plasma ChEI Urine TCP
RBC ChEI Blood TCP Urine TCP 16 The Nolan et al. (1982) and Kisicki et al. (1999) Chlorpyrifos Single Dose Studies in Human Volunteers: Science Assessment John Doherty, PhD, DABT Health Effects Division Office of Pesticide Programs 17 Scope of Presentation The reliability of the analytical data for chlorpyrifos and TCP* and the assessment for ChE and its inhibition with some emphasis on individual variability will be presented.
*TCP = 3,5,6-trichloro-2-pyridinol the principal metabolite of chlorpyrifos. 18 Study Information - Basic Protocols Nolan (1984) Kisicki (1999) Location DOW Chemical Co. Midland, Michigan MDC Harris Laboratory Lincoln, Nebraska Number of Subjects 6 males
12/sex for controls 6/sex/dose group Oral Doses 0.5 mg/kg on tablet 0, 0.5, 1 and 2 mg/ kg in capsules Dermal Doses 5 mg/kg None 19 Study Information ChE activity and analysis for chlorpyrifos and TCP Nolan (1984) Kisicki (1999)
ChE Assessment Michel pH stat (1961) pH/hour Plasma ChE Consistent with original method (CV 3-12%) Not assessed. RBC AChE Consistent with original method (CV 8.5 to 20.2%) Consistent with other labs (CV 6-13%) GC with FP and EC
GC/MS Analytical Method for chlorpyrifos and TCP Levels of Quantization: Chlorpyrifos TCP ~ 5 ng/mL ~ 2.5 5 ng/mL Automated Ellman (1961) IU/L ~ 1 1.2 ng/gm ~2 10 ng/mL 20 Results Analysis for Chlorpyrifos Levels are near the LOQ- Reliability fair.
Nolan Oral: 22 of 48 samples (530 ng/mL) 9 ng/mL in one 0 time. Kisicki 0.5 mg/kg: Not detected. 1 mg/kg : 6 of 156 samples (maximum 5.6 ng/gm). Dermal: 9 of 36 samplings (5-10 ng/mL). 7 and 10 ng/mL in two 0 time. 2 mg/kg: 12 of 150 samples (maximum 18 ng/gm). Poor temporal association with inhibition. Not present when the only subject with inhibition starts to show inhibition. Not in urine
Not in urine 21 Results: Analysis for TCP Ranges show individual variation Nolan (0.5 mg/kg, male) Kisicki (1 mg/kg, male) Time to peak in blood (peak level) 2-24 hours (715 to 1430 ng/mL) Time to peak in urine (peak
level) 3-9 hours (268 to 510 g/hr) Half life based on urinary TCP 27.75.2 hours (21.3-33.9) 28.56.9 (21.6-37.6) Percent recovered in urine 7011% (49-81%) 32.19.7 (23.4-50.8%)
Internal Dose 0.350.06 4-48 hours (300-610 ng/ml) 12-48 hours (935-2642 ng/mL) 0.320.09 22 Results Plasma ChE Inhibition and TCP Nolan Oral Study Basal values 0.870.09 to 1.420.17 are reasonable. All six subjects maximum 71 to 89% inhibition (good
agreement) but time to peak varies (i.e. 6-24 hours). Maximum blood TCP (715 to 1430 ng/mL) usually before maximum inhibition. Approximately 700 800 ng/mL TCP in blood needed for about 57 to 63% inhibition for two subjects. But 996 ng/mL associated with only 30% inhibition in another subject. Correlation of urine (g/hour) TCP with blood (g/mL) and with inhibition confounded because of units and times of collection and ChE assessment. 23 RBC AChE inhibition in the Kisicki Study.
Basal values (i.e. group means) of 8576556 to 9165709 are reasonable. 1.7 to 5.6 ng/mL chlorpyrifos - no inhibition. Blood TCP up to 1300 ng/mL not associated with inhibition. Urine TCP up to 15,323 ng/mL in one subject did not show inhibition. Only one subject displayed RBC AChE inhibition. This subject had highest gastro-intestinal absorption.
Inhibition starts to peak before chlorpyrifos and TCP in the blood and urine peak (next slide). 24 Kisicki Study : RBC AChE inhibition correlation with chlorpyrifos in blood (ng/mL) and TCP in blood and urine). Hour 2 4 8 12 24 36 48 Subject # 56 (QQ ) % Inhibition Chlorpyrifos TCP | Blood
1600 7966 1500 8148 1300 6270 1100 7068 No assessments after 48 hours. (Subject left study) a ND Not detected R = 8148/1600 = 5.1 25 Chlorpyrifos and ChE inhibition Chlorpyrifos [Chlorpyrifos Oxon] (Rapid irreversible inhibition of ChE/AChE) TCP
(Also from other pathways) 26 Blood and urine levels of TCP in females dosed with 2 mg/kg. Subject 49 QQ 51 OR Blood (hour) 490 (8) Urine (hour) 2183 (12) 6064
8.8 5.12 10.9 1300 (8) 600 (24) R 27 Dermal dosing (Nolan study only) Borderline inhibition effect on plasma ChE in 3 of 5 subjects, maximum 26% decrease. RBC AChE not inhibited. Blood TCP at 122 ng/mL with 21% decrease but 36 ng/mL with 26% decrease. No
correlation. Recovery in urine as TCP: 5 mg/kg (five subjects): 1.020.57% 0.5 mg/kg (one subject): 2.6%. 28 Some Applications of the Nolan and/or Kisicki Studies Supports Agency use of low dermal absorption factor (Nolan). Demonstrates BuChE is more sensitive than RBC AChE in humans (Nolan and Kisicki). May support PBPK models.
May support bounding Demonstrates variability of humans to absorb chlorpyrifos from the g-i tract. 29 Summary - Strengths Technical Assessment for ChE/AChE should be reliable in both studies (agree with literature and reasonable CV). Technical analysis for TCP in blood and urine should be reliable (temporal response in both studies and reasonable dose response in Kisicki).
30 Summary Limitations: Both Studies Analytical methods (nano range) are much less sensitive than the epi studies (pico range)*. Variability in TCP analysis humans are not equal*. *Provides challenge for interpreting epi studies. Comparison between Nolan and Kisicki studies confounded because of tablet vs. capsule dosing. Chlorpyrifos present near LOQ and in some 0 time samples (Nolan). Reliability only fair.
31 Summary Limitations: Nolan Study Only one dose resulting in ~70-89% inhibition. Does not establish NOEL. Difficult to establish minimal levels of TCP associated with inhibition. TCP is in units/hour, epi and Kisicki report units/mL. Do not easily compare. 32
Summary Limitations: Kisicki Study Does not include plasma ChE assessment. Only one subject with RBC AChE inhibition limits usefulness. 33 Honeycutt & DeGeare (1993) Science Assessment Wade Britton, MPH Health Effects Division Office of Pesticide Programs 34 Study Information Agricultural
postapplication workers monitored during pruning and picking activities in California citrus Chlorpyrifos (Lorsban 4E) applied once at each of 3 study locations (5-6 lb ai/acre) Study conducted between 1991/1992 35 Sampling Strategy 15 individuals monitored Actual workers and typical durations
Picking 5 individuals (5 at 1 site) Exposure occurred 43 days after application Pruning 10 individuals (5 at each of 2 sites) Exposure occurred 2 days after application 36 Multi-faceted Approach Biological Monitoring* Urine collected for 4 days after exposure Blood sampled 1 day after exposure Pre-exposure samples collected for each Passive Dosimetry
Dermal Inhalation Leaf surface residues 37 Biological Monitoring - Analysis Blood analyzed for plasma and red blood cell (RBC) cholinesterase (ChE) levels Urine analyzed for TCP and creatinine TCP used to calculate chlorpyrifos body burden Creatinine used to evaluate completeness of sample collection
38 Blood ChE - Activity Plasma Avg. (SD) - 0.01 % ( 0.05) Range - 5.1 to 6.6 % Avg. - 1.0 % ( 2.9) (SD) Pruner s (wet) Range -4.4 to 3.0 % Avg. (SD)
- 11 % ( 5.3) Range -14 to -3.5 % Avg. - 3.4 % ( 12) Pruner (SD) s (dry) Range -14 to 16 % Avg. (SD) 30 % ( 16) Range 14 to 50 % Picker s
Avg. (SD) RBC -0.02 % ( 0.05) Range -7.1 to 5.2 % 39 Urine Measurements Urine Absorbed measures Dose (ug/L) (ug/person) 32 ( 4.9) Absorbed Dose (ug/kg, assume 70 kg
0.45 ( 0.071) TCP corrected for pre-study levels Creatinine corrected based upon literature standard (1.8 g/24 hours) 40 Study Strengths Monitored both urine and blood (plasma and RBC ChE) in all workers Actual workers monitored while performing activities in production fields 41 Study Limitations
Not statistically designed to define the relationship between TCP and ChE TCP exposure can occur from many sources Dosimetry possibly limited absorption of chlorpyrifos Potential to underestimate TCP & blood ChE activity 42 Conclusions Represents the best source for occupational worker chlorpyrifos
biological monitoring Provides urine measures and blood plasma and RBC ChE in the same individuals Actual workers, activities and duration 43 Ethics Assessments of Three Pre-Rule Studies of Chlorpyrifos John M. Carley Human Research Ethics Review Officer Office of Pesticide Programs 44
Nolan, et al. (1982) Nolan, R.; Rick, D.; Freshour, N.; and Saunders, J. (1982) Chlorpyrifos: Pharmacokinetics in Human Volunteers Following Single Oral and Dermal Doses. Unpublished study prepared by the Dow Chemical Company under Protocol HEB-DR-0043-4946-4. 28 p. (MRID 124144) Dow AgroSciences (2009) Supplemental Documentation of Ethical Conduct of Nolan et al. Study. E-mail correspondence April 29 through May 8, 2009, between Kenneth Racke and Tom Myers, with attachments. 22 p. 45 Value to Society Defines absorption, distribution, and elimination of oral and dermal doses of chlorpyrifos Contributes to weight of evidence
linking animal data and human epidemiological data 46 Subject Selection Subject Selection Subjects were all salaried Dow employees, recruited through in-house advertisements 6 healthy adult males, screened by a physician not otherwise involved in the research Women of child-bearing age excluded by IRB Nature of endpoints and measures ruled out subject bias in reporting 47 Risks and Benefits
Risks Doses based on earlier studies and pilot pretest, with adequate margins of safety Expected effects Inhibition of plasma ChE but not of RBC ChE No clinical signs Effects reversiblefollowed until full return to baseline Benefits No benefits to subjects 48 Ethics Oversight Approved by Dow Human Health Research Review Committee
Approved by University of Michigan Committee to Review Grants for Clinical Research and Investigation Involving Human Beings Approvals documented; gaps typical for research from this period 49 Informed Consent Subjects were given a copy of protocol to review Subjects were briefed on Study objectives Chlorpyrifos properties Pilot phase results, and study procedures Benefits, including free meals
Confidential handling of data Voluntary participation and freedom to withdraw Subjects signed consent forms reporting that theyd read the protocol and been briefed on the research Subjects were not paid 50 Applicable Standards Standards of Conduct Declaration of Helsinki (1975) FIFRA 12(a)(2)(P) Standards of Acceptability
40 CFR 26.1703 40 CFR 26.1704 51 Compliance with Standards No evidence to suggest research conduct was inconsistent with DoH (1975) Evidence indicates compliance with FIFRA 12(a)(2)(P) No intentional exposure of pregnant or nursing women or of children No clear and convincing evidence of significant
deficiency relative to prevailing standards of research conduct 52 Conclusion If it is deemed scientifically valid and relevant, there are no barriers in FIFRA or in 40 CFR 26.1703 or 26.1704 to EPAs reliance on the Nolan et al. study in actions taken under FIFRA or 408 of FFDCA 53 Honeycutt & DeGeare (1993) Honeycutt, R., and M. DeGeare (1993) Worker Reentry Exposure to Chlorpyrifos in Citrus Treated with Lorsban 4E Insecticide. Unpublished study prepared by H.E.R.A.C., Inc. under study numbers 91-102HE and DECOHEH2.2-1-182(125)B. 950 p. (MRID 43062701) Dow AgroSciences (2009) Supplemental Documenta-tion of Ethical Conduct of Honeycutt
and DeGeare Study. E-mail submission of May 22, 2009 from Kenneth Racke to Tom Myers. 27 p. 54 Value to Society Conducted in response to EPA requirement Part of larger project to monitor agricultural worker exposure to chlorpyrifos Determined ChE activity and TCP residues for workers re-entering treated citrus groves Orange pickers re-entering 43 days after treatment Lemon pruners re-entering 2 days after treatment
Contributes to weight of evidence linking animal data and human epidemiological data 55 Subject Selection Subjects were experienced citrus workers Recruitment was through labor contractor, who may have influenced subject choice to participate Difficulty reported in finding qualified and willing subjects Mingling of subjects in this and companion study of chlorpyrifos handlers
56 Risks and Benefits Risks No increased health risk as I will be doing my job wearing normal protective clothing Unaddressed risks: Heat stress from wearing WBD Differential risks for pickers and pruners
Benefits No benefits to subjects Benefits likely to Dow, EPA, and CDFA 57 Ethics Oversight Protocol review by UCSF Committee on Human Research, brokered by CDFA/CDPR, as was then-standard practice in California Revised CF approved by IRB before use Some amendments affecting subjects may not
have been reviewed by IRB Ethics oversight was closer and is better documented than is typical for worker exposure studies from this period 58 Informed Consent Subjects were briefed in Spanish or English Consent forms used were approved by IRB, included all required elements, but retained erroneous content from companion handler study
CF discussion of MOE should have been revised for pruners Process and form were above average for exposure studies in 1991-92 59 Applicable Standards Standards of Conduct CCR Title 3 6710 (26 Sep 1988) Health of subjects will not be endangered Participants informed of potential risks Medical supervision Incorporation of recommendations by Human Study Committee of California Health and Welfare Agency FIFRA 12(a)(2)(P)
Standards of Acceptability 40 CFR 26.1703 40 CFR 26.1704 60 Compliance with Standards of Conduct Evidence indicates substantial compliance with California rule and with FIFRA 12(a)(2)(P) Active CDPR oversight and approval IRB review and approval Voluntary and informed consent Some protocol amendments should have led to
further revisions to the consent form 61 Compliance with Acceptance Standards 40 CFR 26.1703 No intentional exposure of pregnant or nursing women or of children 40 CFR 26.1704 Not fundamentally unethical No clear and convincing evidence of significant deficiency relative to prevailing standards 62 Conclusion
If it is deemed scientifically valid and relevant, there are no barriers in FIFRA or in 40 CFR 26.1703 or 26.1704 to EPAs reliance on the Honeycutt & DeGeare study in actions taken under FIFRA or 408 of FFDCA 63 Kisicki, et al. (1999) Kisicki, J.; Seip, C.; Combs, M. (1999) A Rising Dose Toxicological Study to Determine the No-Observable-EffectLevels (NOEL) For Erythrocyte Acetylcholinesterase (AChE) Inhibition and Cholinergic Signs and Symptoms of Chlorpyrifos at Three Dose Levels. Unpublished study prepared by MDS Harris Laboratories under Project No. 21438 and Dow AgroSciences Study No. DR K-0044793284. 578 p. (MRID 44811002) Juberg, D.; Mattsson, J. (2008) Dow AgroSciences Response to EPA Query Regarding Two Toxicology Reports. Unpublished document prepared by Dow AgroSciences LLC under Study ID DRJ05142008. 20 p. (MRID 47429401) Juberg, D.; Mattsson, J. (2008) Updated Dow AgroSciences Response to EPA Query Regarding Two Toxicology Reports. Unpublished document prepared by Dow AgroSciences LLC under Study ID DRJ05282008. 27 p. (MRID 47436401)
64 Value to Society Objective was NOEL for RBC ChEI following single oral dose Research undertaken by Dow at their own initiative Determined RBC ChEI and chlorpyrifos and TCP residues in blood and urine May contribute to weight of evidence linking animal data and human epidemiological data 65
Subject Selection Subjects were non-institutionalized subjects consisting of college students and members of the community at large More than the reported 60 were involved 140 candidates who responded to a standard advertisement were screened 60 candidates were enrolled as primary subjects and 22 more as alternates After extensive substitution at the time of check-in, 30
males and 30 females served as treated or control subjects An alternate replacing a primary subject was identified by the same subject number as the person replaced 66 Subject Selection2 Age range 19-54, mean age 31 Inclusion criteria few; exclusion criteria extensive Candidates rejected in screening mainly for drugs or blood chemistry
Enrollees were replaced by alternates mainly because of not showing up at check-in 67 Dose Selection Low dose (0.5 mg/kg) for overlap with Nolan, et al. Because 0.5 mg/kg showed no RBC ChEI in Nolan and no signs, low- and mid-doses (0.5 and 1.0 mg/kg) were administered concurrently in Phase 1 Pause to confirm no effects at 1.0 mg/kg before escalating dose to 2.0 mg/kg in Phase 2
68 Risks to Subjects Not discussed in protocol Consent Form: Potential side effects include . . . improved performance on numerous tests of mental function No adverse effects are anticipated
It may be very unsafe for me to leave the clinic . . . Animal studies indicate little or no risk in humans There are specific and effective antidotes available In all but exceptional cases, persons seriously poisoned . . . recover rapidly leaving no long term effects Risks involved in drawing blood . . . 69 Risks to Subjects2 This procedure may be associated with undesirable effects, some of which are not predictable. However, I understand that in the opinion of MDS Harris medical consultants, those risks are not great enough to keep me from participating 70 Risk Minimization
Vital signs taken periodically Subjects were asked open-ended questions about how they felt Physicians were on call during subject confinement Antidotes described were not required by protocol to be available during test 71 Risk:Benefit Relation
Consent Form states subjects would receive no direct medical benefit, but that the information developed may provide potential benefit to others Protocol is silent concerning societal value of information expected to be gained Relation of risks and benefits not addressed in protocol or by IRB 72 Ethics Oversight Protocol, MSDS, Consent Form, payment, and recruiting advertisement were reviewed and approved by MDS-Harris in-house IRB
Additional changes were reported to have been submitted to IRB direct from sponsor Amendment 1 and revised CF also approved by IRB MDS-Harris IRB holds a Federal-Wide Assurance from OHRP 73 Informed Consent Process Explanation of research and signature of consent form occurred during check-in the evening before treatment
Hectic circumstances at check-in are unlikely to have provided the prospective subject sufficient opportunity to consider whether or not to participate All enrolled primary and alternate subjects had provided blood and urine samples for screening and baseline before receiving an explanation of the research or signing the consent form 74 Informed Consent Form Inappropriate technical language in CF reading grade level for first full paragraph was 17.7 Poor organization, pronoun shifts, mix of dire
warnings and soothing reassurance made it difficult to follow or understand Discussion of risks incomplete and misleading Escalation rule was not explained to subjects, nor were results of Phase 1 incorporated into Consent Form for Phase 2 75 Respect for Subjects Subjects were free to withdraw Subject privacy was not compromised in reports
Subjects were compensated for participation Recruiting and screening processes were needlessly intrusive 76 Unreported Protocol Deviation Protocol: Adverse events, whether serious or non-serious, will be followed to resolution regardless of whether the subject is still participating in the study The only subject with significant ChEI was lost to follow-up 48 h post treatment
This was not acknowledged to be a deviation from the protocol 77 Applicable Standards Standards of Conduct 21 CFR parts 50, 56, and 321 Declaration of Helsinki (1996) FIFRA 12(a)(2)(P) Standards of Acceptability 40 CFR 26.1703 40 CFR 26.1704 78 Compliance with Standards
21 CFR 50 and 56, like the Common Rule, require IRB oversight and prior approval Risk minimization Favorable risk:benefit balance Acceptable informed consent process and consent form Equitable subject selection Fully voluntary participation by subjects Review and approval by the MDS-Harris IRB did not show concern for or ensure compliance with these standards
Deficiencies in consent process made conduct noncompliant with FIFRA 12(a)(2)(P) 79 Conclusions No intentional exposure of pregnant or nursing women or of children No clear and convincing evidence that research was fundamentally unethical In spite of some gaps in the record, there is clear and convincing evidence that conduct of the Kisicki study was significantly deficient relative to the standards of 21 CFR parts 50 and 56, cited by investigators as governing this work
Except under the provisions of 40 CFR 26.1706, EPA is forbidden to rely on this study in actions under FIFRA or FFDCA 80 Charge Questions to the HSRB: Three Pre-Rule Studies of Chlorpyrifos 81 Nolan et al. (1982) 1 Are the blood and urine measurements of chlorpyrifos and/or TCP from the Nolan et al. oral and dermal studies reliable? 2 Are the measurements of cholinesterase activity/inhibition from the Nolan et al. oral and dermal studies reliable? 3 Is there clear and convincing evidence that the conduct of the Nolan et al. study was fundamentally unethical, or significantly deficient relative to the standards of ethical research conduct prevailing
when it was conducted? 82 Honeycutt & DeGeare (1993) 1 Are the blood and urine measurements of chlorpyrifos and/or TCP from the Honeycutt & DeGeare worker biomonitoring study reliable? 2 Are the measurements of cholinesterase activity/inhibition from the Honeycutt & DeGeare worker biomonitoring study reliable? 3 Is there clear and convincing evidence that the conduct of the Honeycutt & DeGeare study was fundamentally unethical, or significantly deficient relative to the standards of ethical research conduct prevailing when it was conducted? 83 Kisicki et al. (1999) 1 Are the blood and urine measurements of chlorpyrifos and/or TCP from the Kisicki et al. oral study reliable? 2 Are the measurements of cholinesterase activity/inhibition from the Kisicki et al. oral study reliable?
3 Is there clear and convincing evidence that the conduct of the Kisicki et al. study was fundamentally unethical, or significantly deficient relative to the standards of ethical research conduct prevailing when it was conducted? 84
Geometry has undefined terms, defined terms, postulates (assumptions that have not been proven, but have "worked" for thousands of years), and theorems (relationships that have been mathematically and logically proven). This presentation will deal with undefined terms and defined terms...
Competency Modeling v. Job Analysis Michael Brannick Discussant Competency Models Are Statements of Values Our company values (e.g.): Integrity Product Knowledge Development of People Goal Directedness (Results Orientation) Content Neutral Derived from beliefs about competitive advantage and human capital, not...
Individual Oral Commentary. The IOC is an Internal Assessment:It is internally assessed by the teacher and externally moderated by the IB at the end of the course.. Weight: 15%. Description: Students are required to engage in a critical examination of...
Today we will use the sum and difference identities for the sine, cosine, and tangent functions Tomorrow we will use the double-angle and half-angle identities for the sine, cosine, and tangent functions 5.4 Sum and Difference Identities * back… to...
Historical recognition in the WTO of the role of competition policy in balancing the exercise of IP rights. Concerns regarding the potential for anti-competitive abuse of rights protected under the TRIPS Agreement were voiced by many countries (especially developing countries)...
2003. Registering of a Non Profit Company - Southern Africa Tourism Services Association NPC, governed by a Memorandum of Incorporation (MOI) with the main objective to manage and administer SATSA, and its affairs managed by members consisting of the NEC...
Injunction - a court order whereby one is required to do or to refrain from doing a specified act. ... How were the new industrial unions different from the older trade union? New Unions Emerge. Workers share same complaints about...
Ready to download the document? Go ahead and hit continue!